ImmunityBio financials
$8.83+3.64%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622.0K | $240.0K | $934.0K |
| Gross profit | $112.5M | $14.7M | $622.0K | $240.0K | $934.0K |
| Gross margin | 99.3% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$256.0M | -$344.2M | -$362.3M | -$351.3M | -$330.3M |
| Net income | -$351.4M | -$413.6M | -$583.2M | -$416.6M | -$346.8M |
| Net margin | −310.2% | −2804.8% | −93761.4% | −173569.6% | −37129.6% |
| Diluted EPS | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 |
| EBITDA | -$240.5M | -$326.6M | -$342.9M | -$332.4M | -$311.2M |
| Operating cash flow | -$304.9M | -$391.2M | -$366.8M | -$337.5M | -$274.4M |
| Free cash flow | -$308.8M | -$398.1M | -$397.3M | -$415.7M | -$308.0M |
| Diluted shares | 919.9M | 700.4M | 508.6M | 399.9M | 389.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $88.3M | $143.4M | $265.5M | $104.6M | $181.1M |
| Short-term investments | $154.5M | $6.4M | $1.0M | $2.5M | $136.0M |
| Total debt | $324.6M | $284.4M | $732.4M | $673.2M | $299.2M |
| Total assets | $501.9M | $382.9M | $504.5M | $362.4M | $468.9M |
| Total liabilities | $1.00B | $871.1M | $971.6M | $790.5M | $712.8M |
| Shareholders' equity | -$499.6M | -$488.1M | -$467.2M | -$428.2M | -$243.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology